QUEST DIAGNOSTICS INC (DGX)
Data as of , from SEC Form 4 filings.
See up to 3 months of DGX. The 7-day demo opens the 1M and 3M ranges and puts DGX on your watchlist.
Start 7-day demoLatest DGX insider trades
- J. E. Davis - OfficerOpen-market sale$2.43M
Michael E. Prevoznik - OfficerOpen-market sale$3.89M
About QUEST DIAGNOSTICS INC (DGX)
The SEC lists QUEST DIAGNOSTICS INC under CIK 0001022079, in medical laboratories. It is grouped with Health Care companies on this site.
DGX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 34,277 | $8.32M |
| Grant or award | 3 | 309 | |
| Option exercise | 2 | 45,354 | |
DGX insider transactions (Form 4)
39123 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Timothy C. Wentworth - Director | Grant or award | Phantom Stock Units | 135 | $0.00 | - | |
| J. E. Davis - Officer | Open-market sale | Common Stock | 10,000 | $242.72 | $2.43M | |
| Michael E. Prevoznik - Officer | Option exercise | Common Stock | 22,677 | $112.17 | $2.54M | |
| Michael E. Prevoznik - Officer | Open-market sale | Common Stock | 16,010 | $242.88 footnote F2 | $3.89M | |
| Michael E. Prevoznik - Officer | Open-market sale | Common Stock | 6,237 | $243.63 footnote F3 | $1.52M | |
| Michael E. Prevoznik - Officer | Open-market sale | Common Stock | 430 | $244.51 footnote F4 | $105K | |
| Michael E. Prevoznik - Officer | Gift | Common Stock | 1,000 | $0.00 | - | |
| Michael E. Prevoznik - Officer | Option exercise | Non-Qualifed Stock Option (right to buy) | 22,677 | $112.17 | $2.54M | |
| ||||||
 Mark E. Delaney - Officer | Open-market sale | Common Stock | 1,600 | $235.18 | $376K | |
 Karthik Kuppusamy - Officer | Other | Common Stock | 37 footnote F1 | $206.81 | $8K | |
| ||||||
 Robert B. Carter - Director | Other | Common Stock | 11 footnote F1 | $206.80 | $2K | |
| ||||||
 Vicky B. Gregg - Director | Grant or award | Common Stock | 72 footnote F1 | $206.81 | $15K | |
| ||||||
| Patrick Plewman - Officer | Other | Common Stock | 46 footnote F1 | $206.81 | $10K | |
| ||||||
| Timothy L. Main - Director | Other | Common Stock | 21 footnote F1 | $206.81 | $4K | |
| ||||||
 Sam Samad - Officer | Grant or award | Common Stock | 102 footnote F2 | $206.81 | $21K | |
| ||||||
 Wright Lassiter III - Director | Other | Common Stock | 6 footnote F1 | $206.81 | $1K | |
| ||||||
| Mark E. Delaney - Officer | Other | Common Stock | 34 footnote F2 | $206.81 | $7K | |
| ||||||
| Timothy C. Wentworth - Director | Grant or award | Phantom Stock Units | 144 | $0.00 | - | |
| Karthik Kuppusamy - Officer | Option exercise | Common Stock | 3,320 | $127.73 | $424K | |
| Karthik Kuppusamy - Officer | Option exercise | Common Stock | 4,827 | $121.81 | $588K | |
| Karthik Kuppusamy - Officer | Open-market sale | Common Stock | 8,147 | $200.00 | $1.63M | |
| Karthik Kuppusamy - Officer | Option exercise | Non-Qualifed Stock Option (right to buy) | 3,320 | $127.73 | $424K | |
| Karthik Kuppusamy - Officer | Option exercise | Non-Qualifed Stock Option (right to buy) | 4,827 | $121.81 | $588K | |
| J. E. Davis - Officer | Open-market sale | Common Stock | 10,000 | $194.14 | $1.94M | |
| Robert B. Carter - Director | Grant or award | Common Stock | 1,142 | $0.00 | - | |
| Vicky B. Gregg - Director | Grant or award | Common Stock | 1,142 | $0.00 | - | |
| Luis Diaz - Director | Grant or award | Common Stock | 1,142 | $0.00 | - | |
| Timothy L. Main - Director | Grant or award | Common Stock | 1,142 | $0.00 | - | |
| Timothy C. Wentworth - Director | Grant or award | Common Stock | 1,142 | $0.00 | - | |
| Tracey Doi - Director | Grant or award | Common Stock | 1,142 | $0.00 | - | |
 Timothy M. Ring - Director | Grant or award | Common Stock | 1,142 | $0.00 | - | |
| Wright Lassiter III - Director | Grant or award | Common Stock | 1,142 | $0.00 | - | |
| Denise M. Morrison - Director | Grant or award | Common Stock | 1,142 | $0.00 | - | |
| Gary M. Pfeiffer - Director | Grant or award | Common Stock | 1,142 | $0.00 | - | |
| Sam Samad - Officer | Grant or award | Common Stock | 108 footnote F2 | $194.70 | $21K | |
| ||||||
| Patrick Plewman - Officer | Other | Common Stock | 49 footnote F1 | $194.70 | $10K | |
| ||||||
| Vicky B. Gregg - Director | Grant or award | Common Stock | 68 footnote F1 | $194.70 | $13K | |
| ||||||
| Robert B. Carter - Director | Other | Common Stock | 7 footnote F1 | $194.70 | $1K | |
| ||||||
| Wright Lassiter III - Director | Other | Common Stock | 6 footnote F2 | $194.70 | $1K | |
| ||||||
Item 5.02
Item 2.02, 9.01
Item 5.07
Item 1.01, 9.01
Recent DGX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Davis J. E. | Officer, Director | 10,000 | $2.43M | View on EDGAR | |
| PREVOZNIK MICHAEL E | Officer | 22,677 |
Stock trades in DGX disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Carol D. MillerRepublican, WV-01 | Sale |
DGX insider trading FAQ
What is the latest insider trade for DGX?
QUEST DIAGNOSTICS INC (DGX) had 12 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for DGX runs to 123 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying DGX stock?
No insider purchases of DGX were filed in the last 90 days.
How many insiders are selling DGX stock?
5 insider sales of DGX were filed in the last 90 days, totaling $8.32M.
Where can I see DGX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects DGX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Timothy C. Wentworth view on EDGAR
- - J. E. Davis view on EDGAR
- - Michael E. Prevoznik view on EDGAR
- - Mark E. Delaney view on EDGAR
- - Karthik Kuppusamy view on EDGAR
- - Robert B. Carter view on EDGAR
- - Vicky B. Gregg view on EDGAR
- - Patrick Plewman view on EDGAR
- - Timothy L. Main view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where DGX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow DGX with a 7-day demo
- DGX on your watchlist
- Every DGX Form 4 filing on record
- Up to 3 months of DGX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
